Publications

Search our bibliography using the filters on the right-hand side.

Displaying 351 through 389 of 389 publications.

Arana A, Rivero E, Egberts TCG. What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):s330-1.

Arana A, Arellano FM, Sánchez-Matienzo D, Perez-Gutthann S. Choosing the measure of relative proportional reporting in quantitative analyses of spontaneous reports. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S324.

Maguire A, Arellano Felix M, Perez-Gutthann S, Arana A. Risk benefit modeling: the use of stochastic simulation for safety evaluations. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S272.

Johannes CB, Schneider GA, Walker AM, Viveash D, Wallis WJ. Increased incidence of lymphoma among patients with rheumatic diseases based on automated insurance claims information. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13:S239.

Johannes CB, Schneider GA, Walker AM, Zhao S, Shibata A. Validation of a propensity score developed using claims data in controlling for health status of rheumatic disease patients initiating etanercept compared with other DMARDS. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(S1):S16.

Sanchez-Matienzo D, Castellsague J, Arana A. Effect of control of confounding in the estimation of the proportional reporting ratio. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S225-6.

Leufkens HG, Arana A. Pharmacoepidemiology adds to orphan drug development. Presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 22, 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep 23; 13(Suppl 1):S256-7.

Maguire A, Melero-Montes M, Saez-Lloret I, Varas-Lorenzo C, Perez-Gutthann S. Changes in hypokalemia and hyperkalemia between 1991 and 2000 in the US according to hypertensive status and treatment. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Sep; 13:S303.

Rothman KJ, Lanes S, Sacks ST. Measuring drug effects means getting a clearer signal. Pharmacoepidemiol Drug Saf. 2004 Aug;13(8):527-8.

Lanza L, Rivero Ferrer M, Fernández C, West WA, Seeger JD. Pregnancy incidence among women with inflammatory skin disorders. Poster presented at the 20th International Conference on Pharmacoepidemiology; August 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Aug; 13(Suppl 1):S206-7.

Varas-Lorenzo C, García-Rodriguez LA, Perez-Gutthann S. Use of oral steroids and the risk of acute myocardial infarction in the UK. Poster presented at the 20th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 2004. Bordeaux, France. [abstract] Pharmacoepidemiol Drug Saf. 2004 Jul; 13(S1):S6.

Rothman KJ. A potential bias in safety evaluation during open-label extensions of randomized clinical trials. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(5):295-8.

Rothman KJ, Lanes S, Sacks ST. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(8):519-23.

Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. Pharmacoepidemiol Drug Saf. 2004 Jan 1;13(4):227-37.

Maguire A, Melero-Montes M, Saez-Lloret I, Varas-Lorenzo C, Perez-Gutthann S. Changes in hypokalemia and hyperkalemia prevalence between 1991 and 2000 in the US according to hypertensive status and treatment. Pharmacoepidemiol Drug Saf. 2004;13:S303.

Mosis G, Gutierrez LP, Dieleman J, Castellsague J, Sturkenboom M. No changes in channeling of COX-2 Specific inhibitors in the first three years after marketing. Poster presented at the ISoP Annual Conference ‘Pharmacovigilance in Clinical Practice’; October 2003. Marrakech, Morocco. [abstract] Pharmacoepidemiol Drug Saf. 2003 Oct; 12(S2):S243.

Mines DI, Wang L, Guo D, Xue S. The incidence of Myasthenia Gravis (MG) in the General Practice Research Database (GPRD): a validation study. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th International Conference on Pharmacoepidemiology; August 22, 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1).

Gimeno V, Castellsague J, Varas-Lorenzo C, Hopkins JS, Eaton SC, Perez-Gutthann S. Gastrointestinal and cardiovascular characterization of users of COX-2 specific inhibitors. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):43.

Garcia-Rodriguez LA, Varas-Lorenzo C, Maguire A, Castellsague J, Gonzalez-Perez A, Perez-Gutthann S, Arellano A. Non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and the risk of acute myocardial infarction in the UK. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):117.

Arana A, Castellsague J, Trave F, Perez-Gutthann S, Rothman KJ, Arellano FM. Early estimation of excess risk of serious cutaneous reactions for newly marketed drugs. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):165.

Varas-Lorenzo C, Maguire A, Perez-Gutthann S. Serum potassium levels, hypertension and antihypertensive treatment in the US adult population: NHANES III (1988-1994). Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):54.

Rivero E, Huerta C, Garcia-Rodriguez LA, Fernandez-Vidaurre C, Abrams BB. The risk of lymphoid neoplasms and other hematological malignancies in patients with atopic dermatitis. Poster presented at the 19th International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(Suppl 1):S110-1.

Arana A, Broeckmans AW. Validity of epidemiological research conducted following Good Clinical Practice Guidelines. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.

Sánchez Matienzo D, Gimeno V, Castellsague J, Arana A. A comparative safety profile of serious skin and hypersensitivity reactions: cOX-s specific inhibitors vs. non-selective NSAIDs and other selected drugs. Presented at the 19th International Conference on Pharmacoepidemiology; 2003. [abstract] Pharmacoepidemiol Drug Saf. 2003; 12(S1):S185.

Sánchez Matienzo D, Gemino V, Castellsague J, Arana A. Safety profile analysis of liver disorders in patients treated with celecoxib and rofecoxib. Presented at the 19th International Conference on Pharmacoepidemiology; 2003.

Rivero E, Varas-Lorenzo C, Rueda de Castro A, Blanch C, Maguire A. Long-term prediction of coronary heart disease risk in a renal transplant clinical trial. Poster presented at the 18th ICPE International Conference on Pharmacoepidemiology; August 21, 2002. Edinburgh, Scotland. [abstract] Pharmacoepidemiol Drug Saf. 2002 Aug 21; 11(Suppl 1):S152.

Rothman KJ, Ray W. Should cases with a 'known' cause of their disease be excluded from study? (Commentary). Pharmacoepidemiol Drug Saf. 2002 Jan 1;11(1):11-4.

Rothman KJ, Ray W. Should epidemiologists exclude cases with a known cause of their disease? Pharmacoepidemiol Drug Saf. 2002;11:11-4.

Duh MS, Rivero E, Varas-Lorenzo C, Funch D, Velentgas P, Walker AM. Lipid data collection practices in U.S. renal transplant centers. Poster presented at the 17th International Conference on Pharmacoepidemiology; August 26, 2001. Toronto, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2001 Aug 26; (Suppl 1):S23.

Arana A, Gutierrez L, Garcia-Rodriguez LA, Perez-Gutthann S. Antiepileptics and liver, testes, cervix uteri and vulvar cancer: a cohort study. Poster presented at the 17th International Conference on Pharmacoepidemiology; August 2001. Toronto, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2001 Aug; 10(supp 1):128.

Gutierrez LP. Patterns and prevalence of use of Vivelle®, Estraderm® and oral premarin among women 45 years and older in a US managed health care setting. Poster presented at the 16th International Conference on Pharmacoepidemiology; August 2000. Barcelona, Spain. [abstract] Pharmacoepidemiol Drug Saf. 2000 Sep; 9(S1):S150-104.

Arana A, Wait S, Santamas M, Ward A, Huybrechts K, Craig T. Thalassemia major: geographical variations in prevalence, survival and treatment patterns. Poster presented at the 16th International Conference on Pharmacoepidemiology; August 2000. [abstract] Pharmacoepidemiol Drug Saf. 9(S1):S96.

Arana A, Castellsague J, Tognoni G, Perez-Gutthann S. Individual daily questionnaires in pharmacoepidemiologic studies and ways of analyzing recurrent events. Comparing tolerability of Desferal® in a real-life setting. Presented at the 13th International Conference on Pharmacoepidemiology; 1997. Orlando, FL. [abstract] Pharmacoepidemiol Drug Saf. 1997 Aug; 6(S2).

Rothman KJ, Lanza L, Lal A, Peskin EG, Dreyer NA. Incidence of pelvic inflammatory disease among women treated for gonorrhea and chlamydia. Pharmacoepidemiol Drug Saf. 1996 Nov 5;5(6):409-14.

Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life-table analysis. J Chronic Dis. 1978 Jan 1;31(8):557-60. doi: 10.1016/0021-9681(78)90043-7

Rothman KJ. A pictorial representation of confounding in epidemiologic studies. J Chronic Dis. 1975 Feb;28(2):101-8.

Rothman KJ, Monson RR. Survival in trigeminal neuralgia. J Chronic Dis. 1973 Jan 1;26(5):303-9.

Rothman KJ, Monson RR. The epidemiology of trigeminal neuralgia. J Chronic Dis. 1973 Jan;26(1):3-12.

Rothman KJ, Keller AZ. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. J Chronic Dis. 1972 Dec;25(12):711-6.